Japanese maker of X-ray analysis and diffraction instruments used in materials research and semiconductor labs.
Japanese maker of X-ray analysis and diffraction instruments used in materials research and semiconductor labs.
Sells costly analytical instruments to labs and factories, and earns repeat income from consumables, service and software on the installed base. Chipmakers' metrology needs and research budgets drive orders. It listed in 2024 after a period of private-equity ownership.
In one line: A niche scientific-instruments maker like a smaller Bruker.
Moat: narrow (process know-how, brand). Specialized X-ray analysis expertise and instrument brand recognition among materials scientists.
Headquarters: Tokyo, Japan · Founded: 1951 · Employees: 1,971
Size Rigaku (268A.T) is a Japan Health Care company (Medical Specialties) with a market value of $1.85B, the 512th largest of 1,370 Japan companies the cockpit tracks. Shares closed at ¥1,318 on 18 Nov 2026.
Performance Over six months the shares fell 53.9%, against +3.5% for the median peer and -1.4% for the Japan market (cap-weighted) — lowest of 20 in its peer set.
Growth Revenue grew 8.9% over the last twelve months (peer median +14.5%); the operating margin is 16.3% (peer median 13.6%).
Valuation It trades at 23.1× forward earnings against a peer median of 29.4× (8th cheapest of 17).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is +15%, so the hurdle is +4 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 0.6 points below its cost of capital (9.1% WACC).
Next results Next results expected around 12 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ¥95.4B | ¥94.2B | ¥90.7B | ¥79.9B | ¥62.7B |
| Revenue growth | — | +4% | +13% | +27% | — |
| Gross profit | ¥54.5B | ¥48.9B | ¥51.3B | ¥43.1B | ¥34.4B |
| EBITDA | ¥21.2B | ¥22.4B | ¥23.4B | ¥19.8B | ¥15.2B |
| Net income | ¥9.61B | ¥11.4B | ¥13.6B | ¥10.9B | ¥911M |
| Free cash flow | ¥5.58B | ¥3.56B | ¥8.74B | ¥8.94B | ¥4.67B |
| Capital expenditure | ¥5.38B | ¥6.65B | ¥6.36B | ¥2.83B | ¥2.72B |
| Total debt | ¥66.7B | ¥62.2B | ¥61.6B | ¥62.1B | ¥63.3B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Rigaku 268A.T | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% |
| Bruker BRKR | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% |
| JEOL 6951.T | $2.12B | -2% | -15% | 12% | 15.5× | 22.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 268A.T | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -11.0% | -2.0% | 4th lowest of 21 |
| 6-month return | -53.9% | +3.5% | lowest of 20 |
| Distance from 52-week high | -61.2% | -21.0% | lowest of 21 |
| Revenue growth (TTM) | +8.9% | +14.5% | 8th lowest of 21 |
| Operating margin | 16.3% | 13.6% | 8th highest of 21 |
| Forward P/E | 23.1× | 29.4× | 8th cheapest of 17 |
| Growth the price implies (Req g, 7 yrs) | 18.3% | 12.6% | 3rd most demanding of 14 |
| Growth delivered (Del g) | +14.5% | +12.9% | 6th highest of 14 |
| Hurdle (Req g minus delivered) | +3.8 pp | -10.3 pp | 3rd most demanding of 14 |
| ROIC minus cost of capital | -0.6 pp | +0.6 pp | 11th highest of 21 |
| EV / EBITDA | 15.7× | 17.9× | 8th cheapest of 16 |
| Net debt / EBITDA | 1.9× | -1.0× | 5th most indebted of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Rigaku 268A.T | Japan | $1.85B | -54% | +9% | 16% | 23.1× | 18.3% | +14.5% |
| Molbio Diagnostics MOLBIO.NS | India | $1.85B | n/a | +35% | 17% | n/a | n/a | n/a |
| SKAN SKAN.SW | Switzerland | $1.85B | +40% | +9% | 11% | 49.5× | 13.8% | +11.7% |
| Fukuda Denshi 6960.T | Japan | $1.84B | +4% | 0% | 19% | 15.4× | -1.6% | -1.0% |
| Medartis MED.SW | Switzerland | $1.86B | +47% | +30% | 2% | 72.8× | n/a | n/a |
| Shandong Weigao Group Medical Polymer 1066.HK | Hong Kong | $1.82B | -8% | +7% | 14% | 8.2× | -12.6% | +2.1% |
| Poly Medicure POLYMED.NS | India | $1.79B | +14% | +25% | 16% | 39.9× | n/a | n/a |
| Nakanishi 7716.T | Japan | $1.78B | +7% | +17% | 21% | 19.0× | 4.8% | +19.7% |
| ChemoMetec A/S CHEMM.CO | Denmark | $1.77B | +107% | +3% | 49% | 46.7× | 19.4% | +12.7% |
| LeMaitre Vascular LMAT | United States | $1.73B | -25% | +12% | 28% | 24.5× | 2.9% | +14.0% |
| Mehow Innovative 301363.SZ | China | $1.72B | -36% | +10% | 21% | 34.2× | 16.4% | +12.9% |
| Embla Medical hf EMBLA.CO | Denmark | $1.72B | +1% | +6% | 14% | 17.2× | -1.9% | +8.3% |
| DENTSPLY SIRONA XRAY | United States | $1.69B | -13% | -1% | 5% | 6.8× | 11.2% | +1.9% |
| Kestra Medical Technologies KMTS | United States | $1.69B | +36% | +61% | -134% | n/a | n/a | n/a |
| Inspire Medical Systems INSP | United States | $1.68B | +32% | 0% | 2% | 41.3× | 28.7% | +51.2% |
| NIPRO 8086.T | Japan | $1.68B | -11% | +5% | 5% | 15.8× | n/a | n/a |
| Bonesupport BONEX.ST | Sweden | $2.06B | +21% | +25% | 25% | 61.5× | 12.6% | +45.4% |
| Veracyte VCYT | United States | $2.06B | -43% | +18% | 16% | 17.1× | 18.0% | +34.5% |
| Butterfly Network BFLY | United States | $1.63B | +38% | +39% | -36% | n/a | n/a | n/a |
| Angelalign Technology 6699.HK | Hong Kong | $1.62B | -8% | +84% | 9% | 52.5× | 16.7% | +25.8% |
| Establishment Labs ESTA | United States | $2.11B | +1% | +38% | -7% | n/a | n/a | n/a |